News

Review top news and interview highlights from the week ending February 24, 2023.

Long term data from 2 clinical trials and expanded access programs were presented at WORLDSymposium 2023.

The patient has not re-started any of his previous Gaucher-specific therapy since receiving AVR-RD-02.

The announcement of a “strategic realignment” comes less than 2 months after the company voluntarily paused the CEDAR clinical trial due to a serious, nula-cel-related adverse event.

Two patients treated with AVR-RD-02 showed clinically meaningful reductions in liver size.

FBX-101 showed promising efficacy and has been well-tolerated so far in the RESKUE trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The assistant professor of medicine and pediatrics at Stanford University discussed updated data from 2 studies of Orca-T cell therapy.

The gene therapy was approved in the US in the same indication in November 2022.

By 3 months, 12 of 17 patients treated with a full cycle of EG-70 achieved a complete response.

The assistant professor of medicine at Vanderbilt University Medical Center discussed results from a retrospective analysis presented at the 2023 Tandem Meetings.

It was found that ctDNA levels at 28 days post-treatment were significantly higher for patients who ultimately progressed by 90 days post-treatment.

The assistant professor of medicine, bone marrow transplantation and cellular therapy, Stanford, discussed favorable data from a real-world experience study.

The hematologist/oncologist at Cincinnati Children’s discussed unfavorable outcomes with tisa-cel reinfusion in patients with B-cell acute lymphocytic leukemia.

Median PFS was 13.3 months in the ide-cel arm, compared to 4.4 months for the SOC arm.

The locum consultant of pediatric BMT and leukemia at Royal Manchester Children’s Hospital discussed the limited distribution model of arsa-cel in Europe.

Patients with large B-cell lymphoma had an ORR of 68% and a CR rate of 53%.

No adverse events related to RP-L201 have been reported to date.

Among the 14 patients with relapsed/refractory mantle cell lymphoma who were treated with LV20.19 CAR in the trial, the overall response at 28 days post-treatment was 100%.

Long-term hematologic stability has been observed in at least 6 out of 10 patients with at least 12 months of follow-up.

The associate professor of medicine at Medical College of Wisconsin discussed trials assessing the dual, CD19/CD20-targeting CAR T therapy.

Among 43 patients who had EBV+ PTLD following allogeneic hematopoietic cell transplant or solid organ transplant, the overall response rate was 51.2%.

Neither patient treated with RP-L301 required RBC transfusions at any point post-engraftment.

The spine surgeon from The Orthopedic Center of St. Louis discussed unmet needs in the lumbar DDD population.

Antiviral responses increased until peaking at week 24.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A third price model to be tested will limit the price of generic drugs for chronic conditions to $2 under Medicare plan D.

Based on 4-week follow-up data from the first patient, an independent safety evaluation committee approved the trial’s continuation.